Sugi Predict

Sugi Predict / Compounds / SCHEMBL1109746

SCHEMBL1109746

SCHEMBL1109746

Cc1cc(C)c(C(C)(C)O)c(C)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.39
▸ CA2 P00918 2/20 0.39
▸ POLB P06746 1/20 0.39
▸ TYR P14679 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ RAPGEF4 Q8WZA2 4/20 0.38
▸ KDM4E B2RXH2 3/20 0.37
▸ LMNA P02545 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ TP53 P04637 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ HTT P42858 1/20 0.34
▸ L3MBTL1 Q9Y468 2/20 0.33
▸ SELL P14151 1/20 0.33
▸ SELP P16109 1/20 0.33
▸ SELE P16581 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ MMP1 P03956 1/20 0.33
▸ MMP2 P08253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18535704 0.83 ALDH1A1 (0.39) ALDH1A1CA2POLBTYRSMN1; SMN2
SCHEMBL8388461 0.77 ALDH1A1 (0.42) ALDH1A1CA2POLBTYRSMN1; SMN2
SCHEMBL22914917 0.77 ALDH1A1 (0.42) ALDH1A1CA2POLBTYRSMN1; SMN2
SCHEMBL18802800 0.76 SMN1; SMN2 (0.48) ALDH1A1CA2POLBTYRSMN1; SMN2
SCHEMBL18288154 0.74 PGK1 (0.43) ALDH1A1CA2POLBTYRSMN1; SMN2
SCHEMBL11954794 0.74 ALDH1A1 (0.58) ALDH1A1CA2POLBTYRSMN1; SMN2
SCHEMBL17389037 0.74 KDM4E (0.43) ALDH1A1CA2SMN1; SMN2KDM4ELMNA
SCHEMBL15957641 0.72 ATM (0.46) ALDH1A1CA2POLBKDM4ECA1
SCHEMBL6025576 0.72 RAPGEF4 (0.38) ALDH1A1CA2POLBTYRSMN1; SMN2
SCHEMBL3973787 0.72 SELL (0.46) ALDH1A1CA2POLBTYRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1937407-B1 SOLUTIONS OF ANHYDROUS LANTHANIDE SALTS AND ITS PREPARATION UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) 2015-04-22 — — EP disclosed
EP-1937407-B1 SOLUTIONS OF ANHYDROUS LANTHANIDE SALTS AND ITS PREPARATION UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) 2015-04-22 — — EP disclosed
EP-1405840-B1 Organometallic reaction method ZEON CORP (JP) 2014-08-20 — — EP disclosed
US-20140171427-A1 Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-06-19 — — US disclosed
EP-2217611-B1 NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS MERCK SHARP & DOHME (US) 2013-07-31 — — EP disclosed
US-8470982-B2 Solutions of anhydrous lanthanide salts and its preparation LUDWIG-MAXIMILIANS-UNIVERSITAET (DE) 2013-06-25 — — US disclosed
US-8470982-B2 Solutions of anhydrous lanthanide salts and its preparation LUDWIG-MAXIMILIANS-UNIVERSITAET (DE) 2013-06-25 — — US disclosed
US-8470982-B2 Solutions of anhydrous lanthanide salts and its preparation LUDWIG-MAXIMILIANS-UNIVERSITAET (DE) 2013-06-25 — — US disclosed
CN-101277763-B Anhydrous lanthanide salt solutions and their preparation UNIV MUENCHEN L MAXIMILIANS 2012-08-22 — — CN disclosed
US-8017813-B2 Process for production of cycloalkyl alkyl ethers ZEON CORPORATION (JP) 2011-09-13 — — US disclosed
EP-1937407-A1 SOLUTIONS OF ANHYDROUS LANTHANIDE SALTS AND ITS PREPARATION Ludwig-Maximilians-Universität München (DE) 2008-07-02 — — EP disclosed
WO-2007026014-A1 SOLUTIONS OF ANHYDROUS LANTHANIDE SALTS AND ITS PREPARATION LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) 2007-03-08 — — WO disclosed
WO-2007026014-A1 SOLUTIONS OF ANHYDROUS LANTHANIDE SALTS AND ITS PREPARATION LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) 2007-03-08 — — WO disclosed
EP-1759765-A1 Solutions of anhydrous lanthanide salts and its preparation Ludwig-Maximilians-Universität München (DE) 2007-03-07 — — EP disclosed
EP-1759765-A1 Solutions of anhydrous lanthanide salts and its preparation Ludwig-Maximilians-Universität München (DE) 2007-03-07 — — EP disclosed
US-7002010-B2 Process for the preparation of morpholinones as light stabilizers CIBA SPECIALTY CHEMICALS CORPORATION (US) 2006-02-21 — — US disclosed
US-20050065060-A1 Solvents containing cycloakyl alkyl ethers and process for production of the ethers ZEON CORPORATION (JP) 2005-03-24 — — US disclosed
CN-1543449-A Solvent containing cycloalkyl alkyl ether and preparation method thereof �ձ�������ʽ���� 2004-11-03 — — CN disclosed
EP-1405840-A1 SOLVENTS CONTAINING CYCLOALKYL ALKYL ETHERS AND PROCESS FOR PRODUCTION OF THE ETHERS Zeon Corporation (JP) 2004-04-07 — — EP disclosed
US-20040024252-A1 Process for the preparation of morpholinones as light stabilizers CIBA SPECIALTY CHEMICALS CORP. 2004-02-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024252-A1 Process for the preparation of morpholinones as light stabilizers TMT1A, SEM1, MITF ALDH1A1 34/4885CA2 3841/4885POLB 3060/4885
US-20140171427-A1 Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels KCNJ2, TRPV1, KCNJ1 ALDH1A1 1614/4885CA2 226/4885POLB 4630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.